Anzeige
Meldung des Tages: Gold auf 6.300 USD? Diese Aktie könnte der geheime Hebel sein

Lunai Bioworks News

Aktie
WKN:  A41K8P ISIN:  US29350E2037 US-Symbol:  LNAI Branche:  Biotechnologie Land:  USA
0,3207 $
-0,0192 $
-5,65%
0,27137 € 15.04.26
Depot/Watchlist
Marktkapitalisierung *
190,46 Mio. €
Streubesitz
100,00%
KGV
-0,27
Index-Zuordnung
-

Lunai Bioworks News

15.04.26 - PR Newswire
Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships
Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships PR Newswire
07.04.26 - PR Newswire
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-​Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; ...
26.03.26 - PR Newswire
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery ...
19.03.26 - PR Newswire
Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model
Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development ...
19.02.26 - PR Newswire
Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping
Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping PR Newswire
13.02.26 - PR Newswire
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC PR Newswire
09.02.26 - PR Newswire
Lunai Bioworks, Inc. Issues Letter to Shareholders
Lunai Bioworks, Inc. Issues Letter to Shareholders PR Newswire
09.02.26 - PR Newswire
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-​Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data PR Newswire
27.01.26 - PR Newswire
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons PR Newswire
26.01.26 - PR Newswire
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-​Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery PR Newswire
25.11.25 - PR Newswire
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models PR Newswire
07.11.25 - PR Newswire
Lunai Bioworks schafft es, sowohl primäre als auch metastasierte Bauchspeicheldrüsentumoren in präklinischen humanisierten Modellen komplett zurückzubilden, was einen Durchbruch in der allogenen Krebsimmuntherapie bedeutet
Lunai Bioworks schafft es, sowohl primäre als auch metastasierte Bauchspeicheldrüsentumoren in präklinischen humanisierten Modellen komplett zurückzubilden, was einen ...
06.11.25 - PR Newswire
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer ...
05.11.25 - PR Newswire
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer ...
29.07.25 - PR Newswire
AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks
AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks PR Newswire
29.07.25 - PR Newswire
AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks
AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks PR Newswire
10.06.25 - PR Newswire
Smart Healthcare Is Taking Over. Here's Where the Money's Headed
Smart Healthcare Is Taking Over. Here's Where the Money's Headed PR Newswire
10.06.25 - PR Newswire
Smart Healthcare Is Taking Over. Here's Where the Money's Headed
Smart Healthcare Is Taking Over. Here's Where the Money's Headed PR Newswire
23.05.25 - PR Newswire
AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the Charge
AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the Charge PR Newswire
23.05.25 - PR Newswire
AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the Charge
AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the Charge PR Newswire

Newssuche

Videos

newspaper
07.04.26 0,00%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »